Literature DB >> 3043779

Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine.

P F Halloran1, M A Aprile, V Farewell, D Ludwin, E K Smith, S Y Tsai, R A Bear, E H Cole, S S Fenton, D C Cattran.   

Abstract

We examined the factors determining graft survival in 200 consecutive cadaveric renal transplants managed on a quadruple-therapy protocol: Minnesota antilymphoblast globulin, cyclosporine, azathioprine, and low-dose prednisone. Perioperative central venous pressure monitoring and volume expansion were emphasized. To avoid CsA nephrotoxicity in the early posttransplant period, patients were treated with ALG until renal function was established (a mean of 7 days). Therapeutic CsA levels were achieved before ALG was discontinued. Azathioprine was used to supplement CsA in patients with nephrotoxicity or rejection. Twelve-month graft survival was 85% (first transplants 86%, retransplants 79%), with patient survival of 95%. ALG was not associated with excessive clinical cytomegalovirus infections, which occurred in 5% of patients, or with malignancy. When 3 technical failures were excluded, an analysis of numerous factors in the pretransplant and peritransplant period revealed that the strongest correlate of one-year graft survival was early renal function. Grafts with delayed function (DF) had 75% survival, compared with 91% for grafts with good early function (EF). A multivariate analysis confirmed this association: the relative risk of graft loss was increased 2.86 times for DF compared with EF. The mechanism of the deleterious effect of DF was apparently multifactorial: the DF group, by definition, contained all the kidneys that never functioned, but some risk also persisted in kidneys that achieved function. One reason for this may be that DF kidneys that achieved function had higher mean serum creatinine values at 1 month: elevated serum creatinine values at 1 month were strongly associated with increased risk of graft loss regardless of initial function. There was also a higher number of rejection episodes diagnosed in the DF group. These observations suggest that early renal function is a major determinant of graft outcome and should be a target for efforts to further improve renal graft survival.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3043779

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

Review 1.  Chronic rejection and late renal allograft dysfunction.

Authors:  J Laine; C Holmberg; P Häyry
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

Review 2.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

3.  A mouse model of renal ischemia-reperfusion injury solely induced by cold ischemia.

Authors:  Jin Wei; Yingliang Wang; Jie Zhang; Lei Wang; Liying Fu; Byeong J Cha; Jacentha Buggs; Ruisheng Liu
Journal:  Am J Physiol Renal Physiol       Date:  2019-07-10

Review 4.  Delayed graft function in the kidney transplant.

Authors:  A Siedlecki; W Irish; D C Brennan
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

5.  Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver.

Authors:  L Bergamaschini; G Gobbo; S Gatti; L Caccamo; P Prato; M Maggioni; P Braidotti; R Di Stefano; L R Fassati
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

6.  Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes.

Authors:  Miguel Ascon; Dolores B Ascon; Manchang Liu; Chris Cheadle; Chaitali Sarkar; Lorraine Racusen; Heitham T Hassoun; Hamid Rabb
Journal:  Kidney Int       Date:  2008-12-17       Impact factor: 10.612

7.  Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study.

Authors:  Maria E Hollmen; Lauri E Kyllönen; Kaija A Inkinen; Martti L T Lalla; Jussi Merenmies; Kaija T Salmela
Journal:  Crit Care       Date:  2011-05-05       Impact factor: 9.097

8.  Serum neutrophil gelatinase-associated lipocalin and recovery of kidney graft function after transplantation.

Authors:  Maria E Hollmen; Lauri E Kyllönen; Jussi Merenmies; Kaija T Salmela
Journal:  BMC Nephrol       Date:  2014-07-28       Impact factor: 2.388

9.  Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.

Authors:  Matthew P Welberry Smith; Alexandre Zougman; David A Cairns; Michelle Wilson; Tobias Wind; Steven L Wood; Douglas Thompson; Michael P Messenger; Andrew Mooney; Peter J Selby; Andrew J P Lewington; Rosamonde E Banks
Journal:  Kidney Int       Date:  2013-06-05       Impact factor: 10.612

10.  Impact of kidney donor hemostasis on risk of complications after transplantation--preliminary outcomes.

Authors:  Iza Iwan-Ziętek; Zbigniew Ziętek; Tadeusz Sulikowski; Andrzej Ciechanowicz; Marek Ostrowski; Danuta Rość; Marek Kamiński
Journal:  Med Sci Monit       Date:  2013-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.